TransMolecular, Inc. Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc. today announced new data highlighting the anti-angiogenic and tumor-targeting properties of TM601 in a poster presentation and in a published abstract at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). In a clinical study of patients with recurrent glioblastoma, the first cohort of patients analyzed showed correlative reductions in vascular perfusion and prolongation of progression-free survival. A separate clinical study, utilizing radiolabeled TM601, demonstrated highly specific tumor uptake of intravenously delivered 131I-TM601 in several different primary and metastatic tumor types, including glioma, metastatic melanoma, pancreatic cancer, prostate cancer and non-small cell lung cancer. Of note, selective tumor-specific uptake of 131I-TM601 was observed in six cases of melanoma with metastases in the brain, demonstrating that 131I-TM601 localized to metastatic tumors across the blood-brain barrier. TM601 is a novel, wholly synthetic peptide, found to have robust anti-angiogenic activity in neovascular diseases, including cancer and ophthalmic disease.

Back to news